Any current/future new fundraising through debt or equity?

No specific mention of new fundraising through debt or equity was made in the call. Finance costs are within the normal range, linked to periodic working capital utilization and ongoing capex. The company maintains regular maintenance capex of around INR 10-12 crores annually; no major new capex is planned unless an M&A opportunity arises. The focus for growth funding appears to be internal accruals and strategic acquisitions rather than new debt or equity issuance at this time. Any expansion, including acquisitions, is being evaluated carefully for return on capital and strategic fit before p

Any current/future capex/capital investment/strategic investment?

Windlas Biotech is undergoing capex for debottlenecking in Oral Solid Dosage (OSD) expected to complete by Q2 FY25. They plan to acquire a plant by the end of FY25, mainly for oral solids capacity expansion, similar dosage form. No major capex is planned beyond current plant expansion and the acquisition, except routine maintenance capex of INR 10-12 crores annually. The acquisition under consideration aims for adding quality assets with established customers, targeting revenue potential around INR 200-250 crores. Injectable facility built with spare floor for quick capacity addition; revenue

Future growth expectations in sales/revenue/volumes?

The company delivered 21% Y-o-Y revenue growth to INR175 crores in Q1 FY'25, with all business verticals growing. CDMO vertical showed 23% Y-o-Y growth, driven by new product launches, wallet share expansion, and operational excellence. Trade generics and institutional vertical grew 14% Y-o-Y, backed by expanded distribution and more institutions/products added. Exports grew 10% Y-o-Y, with plans to grow via acquisition of European market authorizations, expanding portfolio and geographic reach. Injectable revenue expected to start mid Q3 FY'25, positively impacting profitability and m

Future growth expectations in earnings/operating earnings/profits/EPS?

Windlas Biotech reported strong Q1 FY25 results with 21% Y-o-Y revenue growth and 12% EPS growth (INR6.47 vs INR5.79). EBITDA margins expected to improve as injectable facility revenue starts from mid-Q3 FY25. CEO Komal Gupta emphasized sustained growth across all verticals without specific quarterly guidance but conveyed optimism. Trade generics and institutional vertical expected to continue current growth momentum. CDMO vertical growth driven by business development, new client additions, new product launches, and wallet share expansion. Expansion of capacities via brownfield projects and a

Windlas Biotech LtdQ1 FY25Pharmaceuticals & Biotechnology

Windlas Biotech Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹923.4P/E: 28.7Market Cap: ₹1.9K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

The company delivered 21% Y-o-Y revenue growth to INR175 crores in Q1 FY'25, with all business verticals growing.
CDMO vertical showed 23% Y-o-Y growth, driven by new product launches, wallet share expansion, and operational excellence.
Trade generics and institutional vertical grew 14% Y-o-Y, backed by expanded distribution and more institutions/products added.
Exports grew 10% Y-o-Y, with plans to grow via acquisition of European market authorizations, expanding portfolio and geographic reach.
Injectable revenue expected to start mid Q3 FY'25, positively impacting profitability and margins thereafter.
Capacity expansions underway, including Brownfield expansions and acquisitions, aiming for INR1000 crore revenue capacity by end FY'25.
No major capex beyond plant acquisition and ongoing expansions expected till FY'25 unless new M&A arise.
Optimistic medium-term growth expected across verticals, with growing client base and wallet share, supported by new capacities and acquisitions.

Margin guidance

Category 3

Windlas Biotech reported strong Q1 FY25 results with 21% Y-o-Y revenue growth and 12% EPS growth (INR6.47 vs INR5.79).
EBITDA margins expected to improve as injectable facility revenue starts from mid-Q3 FY25.
CEO Komal Gupta emphasized sustained growth across all verticals without specific quarterly guidance but conveyed optimism.
Trade generics and institutional vertical expected to continue current growth momentum.
CDMO vertical growth driven by business development, new client additions, new product launches, and wallet share expansion.
Expansion of capacities via brownfield projects and acquisition planned to support revenue target of INR1000 crores by FY25 end.
Margins and ROCE anticipated to improve over next 1-2 years as injectable ramp-up progresses and operating leverage kicks in.
Management cautious on giving exact growth percentages but remains positive on medium-term growth prospects driven by internal execution and regulatory factors.

See what Windlas Biotech Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

No specific mention of new fundraising through debt or equity was made in the call.
Finance costs are within the normal range, linked to periodic working capital utilization and ongoing capex.
The company maintains regular maintenance capex of around INR 10-12 crores annually; no major new capex is planned unless an M&A opportunity arises.
The focus for growth funding appears to be internal accruals and strategic acquisitions rather than new debt or equity issuance at this time.
Any expansion, including acquisitions, is being evaluated carefully for return on capital and strategic fit before proceeding.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for Windlas Biotech Limited. However, relevant insights related to demand and growth outlook include: - The company has a growing customer base and has added new customers and products consistently, especially in CDMO and trade generics verticals. - There is strong demand momentum and pipeline, with no capacity constraints anticipated in the near term. - The company is expanding capacity (brownfield initiatives, injectable facility expansion) to meet future demand. - Business development efforts continue to add wallet share and new business across verticals. - Management expressed confidence in continued growth supported by robust internal execution and external market opportunities. - No explicit quantified order book or pending order values are disclosed as of Q1 FY25. In summary, while specific order book numbers are not provided, Windlas Biotech is positioned for strong order inflows and growth with expanding capacity and client base.

See what Windlas Biotech Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Windlas Biotech is undergoing capex for debottlenecking in Oral Solid Dosage (OSD) expected to complete by Q2 FY25.
They plan to acquire a plant by the end of FY25, mainly for oral solids capacity expansion, similar dosage form.
No major capex is planned beyond current plant expansion and the acquisition, except routine maintenance capex of INR 10-12 crores annually.
The acquisition under consideration aims for adding quality assets with established customers, targeting revenue potential around INR 200-250 crores.
Injectable facility built with spare floor for quick capacity addition; revenue generation expected from mid-Q3 FY25.
Export expansion facilitated by acquisition of European market authorizations.
Focus on Brownfield expansions rather than new greenfield projects unless dictated by M&A opportunities.

Track Windlas Biotech Ltd — get its next earnings analysis in your feed

How does Windlas Biotech Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisWindlas Biotech Ltd

Rev 3Mar 3

See where Windlas Biotech Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Windlas Biotech Ltd rank in Pharmaceuticals & Biotechnology?

Compare Windlas Biotech Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Windlas Biotech Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Windlas Biotech Ltd Q1 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Windlas Biotech Ltd rank in Pharmaceuticals & Biotechnology?

Continue your research

What Windlas Biotech Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season